Corindus Vascular Robotics, Inc. (CVRS) Analysts See $-0.05 EPS

October 13, 2018 - By Winifred Garcia

Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) Logo

Analysts expect Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) to report $-0.05 EPS on November, 6.They anticipate $0.01 EPS change or 25.00 % from last quarter’s $-0.04 EPS. After having $-0.06 EPS previously, Corindus Vascular Robotics, Inc.’s analysts see -16.67 % EPS growth. The stock increased 2.34% or $0.03 during the last trading session, reaching $1.31. About 229,388 shares traded. Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) has declined 26.71% since October 13, 2017 and is downtrending. It has underperformed by 42.33% the S&P500.

Corindus Vascular Robotics, Inc. designs, makes, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures. The company has market cap of $247.54 million. The firm offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. It currently has negative earnings. The Company’s CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>